These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28686318)

  • 41. LRRK2 and the Immune System.
    Dzamko NL
    Adv Neurobiol; 2017; 14():123-143. PubMed ID: 28353282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs.
    Ahamadi M; Conrado DJ; Macha S; Sinha V; Stone J; Burton J; Nicholas T; Gallagher J; Dexter D; Bani M; Boroojerdi B; Smit H; Weidemann J; Chen C; Yang M; Maciuca R; Lawson R; Burn D; Marek K; Venuto C; Stafford B; Akalu M; Stephenson D; Romero K;
    Clin Pharmacol Ther; 2020 Mar; 107(3):553-562. PubMed ID: 31544231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Zabetian CP; Mata IF;
    Mov Disord; 2017 Sep; 32(9):1330-1331. PubMed ID: 28657124
    [No Abstract]   [Full Text] [Related]  

  • 46. LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study.
    Skorvanek M; Rizig M; Athanasiou-Fragkouli A; Necpal J; Straka I; Tamas G; Kurca E; Mosejova A; Han V; Lorincova T; Ostrozovicova M; Liesenerova S; Levicka P; Fajcikova L; Minar M; Valkovic P; Mákos O; Kelemen A; Grofik M; Cibulka M; Jama F; Houlden H;
    Parkinsonism Relat Disord; 2021 Feb; 83():110-112. PubMed ID: 33561776
    [No Abstract]   [Full Text] [Related]  

  • 47. Generation of induced pluripotent stem cells from a patient with Parkinson's disease carrying LRRK2 p.I2012T mutation.
    Lin CH; Cheng YC; Lin HI; Ho MC; Hsu YH; Wen CH; Ko HW; Lu HE; Huang CY; Hsieh PCH
    Stem Cell Res; 2017 Dec; 25():123-127. PubMed ID: 29127874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
    Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Sambin S; Lavisse S; Decaix C; Pyatigorskaya N; Mangone G; Valabrègue R; Arnulf I; Cormier F; Lesage S; Lehericy S; Remy P; Brice A; Corvol JC
    Mov Disord; 2022 Feb; 37(2):428-430. PubMed ID: 34668587
    [No Abstract]   [Full Text] [Related]  

  • 52. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.
    Lu CS; Simons EJ; Wu-Chou YH; Fonzo AD; Chang HC; Chen RS; Weng YH; Rohé CF; Breedveld GJ; Hattori N; Gasser T; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2005 Dec; 11(8):521-2. PubMed ID: 16256409
    [No Abstract]   [Full Text] [Related]  

  • 55. LRRK2 mutations in Basque patients with Parkinson's disease.
    Zarranz JJ; Gómez-Esteban JC
    Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
    [No Abstract]   [Full Text] [Related]  

  • 56. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
    Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
    Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.
    Trinh J; Amouri R; Duda JE; Morley JF; Read M; Donald A; Vilariño-Güell C; Thompson C; Szu Tu C; Gustavsson EK; Ben Sassi S; Hentati E; Zouari M; Farhat E; Nabli F; Hentati F; Farrer MJ
    Neurobiol Aging; 2014 May; 35(5):1125-31. PubMed ID: 24355527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.